On June 17, 2026, Nyxoah SA received approximately $15.0 million (€13.8 million) from the second tranche of its existing loan facility with the European Investment Bank. Additionally, the company announced an extraordinary shareholders' meeting scheduled for July 9, 2026. Nyxoah SA is a medical device company that develops neuromodulation therapies.
